Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 51
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2027HMGB1ProteinHumanUpregulated in HCC PredictiveHCC treated with sorafenib and with HAIC v/s Patients with Pre-treatment. p < 0.05Tissue28474222
2060UracilMetaboliteMiceDownregulated Potential Predictive *Cancer v/s Normal; Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2061cis-Aconitate acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2062D-4-PhosphopantothenateMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2063ProgesteroneMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20645-Thymidylic acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20652-Phospho-d-glyceric acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2066NiacinamideMetaboliteMiceUpregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2067CortisoneMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2068Imidazoleacetic acid ribotideMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20693-Methyl-2-oxovaleric acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2070PseudoephedrineMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20714-PhosphopantothenoylcysteineMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2072Pantetheine 4-phosphateMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2073Hippuric acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20743-Hydroxyanthranilic acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2075GlycineMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2076CreatineMetaboliteMiceUpregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2077CortisolMetaboliteMiceUpregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2078Allantoic acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2079Pantothenic acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2080CreatinineMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2081UreaMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
20825-Hydroxyindoleacetic acidMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2083PhytosphingosineMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.05Urine and Plasma27077962
2084Imidazoleacetic acid ribosideMetaboliteMiceDownregulated Potential Predictive *Drug treated group v/s control group p < 0.01Urine and Plasma27077962
2111qEASLMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2112vRECISTMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2115Galectin-1ProteinHuman High pretreatment galectin-1 levels remained an independent predictor of shorter progression-free survival and overall survival PredictiveHCC patients treated with sorafenib vs HCC untreated patients p < 0.01Serum25850433
2120D-glucurono-6,3-lactoneMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2121glycerol-3-phosphateMetaboliteMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2122pyruvic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2123lithocholic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
21242-pyrocatechuic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2125prostaglandin E1MetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2168CYP1A1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2169CYP1B1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2170GDF15RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2171SERPINE1RNAsHuman cell linesUpregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2172SOS1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2173RASD1RNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2174MRASRNAsHuman cell linesUpregulated in hepatoma cell Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2175NR1H4RNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2176PALMDRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2177TXNIPRNAsHuman cell linesDownregulated in hepatoma cells Potential Predictive *Normal vs hepatoma cells treated with emodin p < 0.0001Cells19895793
2361UBA2RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2362ZNF185RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2363FOXF1RNAsHuman cell lineUpregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2364UBE4BRNAsHuman cell lineDownregulated in IFN-alpha drug-tolerant cells Potential Predictive *IFN-α treatment tolerant v/s non tolerant cells FDR <0.5%.Cell line 15709204
2428IGFBP7Protein and RNAsHumanDownregulated in IFN-resistant cells (with fold change 2.963) PredictiveIGFBP7-positive HCC patients v/s IGFBP7-negative HCC patients p < 0.05Cell line and Tissue20407444

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top